Long-term outcomes of prostate cancer patients treated with combined brachytherapy and maximal androgen blockade
To explore the prognostic factors of prostate cancer (PCa) patients and evaluate the effect of brachytherapy on survival time. A total of 289 PCa were recruited to collect their clinical and survival data. And their possible prognostic factors were analyzed. A further comparison of 5-year cumulative...
Gespeichert in:
| Veröffentlicht in: | Zhong hua yi xue za zhi 2013-11, Vol.93 (42), p.3351-3354 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3354 |
|---|---|
| container_issue | 42 |
| container_start_page | 3351 |
| container_title | Zhong hua yi xue za zhi |
| container_volume | 93 |
| creator | Luo, Yong Wei, Neng-bao Zhao, Jia-hui Cui, Xin-hao Li, Ming-chuan Lin, Yun-hua Hou, Zhu Han, Yi-li Jiang, Yong-guang |
| description | To explore the prognostic factors of prostate cancer (PCa) patients and evaluate the effect of brachytherapy on survival time.
A total of 289 PCa were recruited to collect their clinical and survival data. And their possible prognostic factors were analyzed. A further comparison of 5-year cumulative survival rate was made between the patients treated by maximal androgen blockade (MAB) and those on MAB plus brachytherapy.
Their median survival time was 73 (7-144) months. And the 1, 3 and 5-year survival rates were 93.1%, 81.0% and 60.2% respectively. Univariate analysis indicated that prostate volume, basal level of prostate-specific antigen (PSA), Gleason score, tumor stage, PSA nadir, time PSA decreasing to nadir and brachytherapy were all predictive factors for survival time. And multivariate analysis further demonstrated that Gleason score, tumor stage and PSA nadir were independent prognostic indicators. And the combination therapy based on brachytherapy could significantly increase the 5-year cumulative |
| doi_str_mv | 10.3760/cma.j.issn.0376-2491.2013.42.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1490770131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490770131</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-d150ed8d316c828d66d68f7e4827b737c983285205d035365d6a299100e7a8303</originalsourceid><addsrcrecordid>eNo9kE1PwzAMhnMAsQn2F1COu7Q4SdukRzTxJU3iAucqTbyt0KYlSQX79wQxONl-9MiyX0LWDHIhK7gxg87f8i4El0MCGS9qlnNgIi94DiDPyPKfL8gqhK6FQoqaA2cXZMGLgikQsCTTdnT7LKIf6DhHMw4Y6Lijkx9D1BGp0c6gp5OOHboYaPSYsKWfXTzQpLedS1PrtTkc4wG9no5UO0sH_dUNuv_p_bhHR9t-NO_a4hU53-k-4OpUL8nr_d3L5jHbPj88bW632cR4FTPLSkCrrGCVUVzZqrKV2kksFJetFNLUSnBVcigtiFJUpa00r2sGgFIrAeKSrH_3plc-ZgyxGbpgsO-1w3EODStqkDIlxpJ6fVLndkDbTD6d7o_NX0riG_DEbaA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490770131</pqid></control><display><type>article</type><title>Long-term outcomes of prostate cancer patients treated with combined brachytherapy and maximal androgen blockade</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Luo, Yong ; Wei, Neng-bao ; Zhao, Jia-hui ; Cui, Xin-hao ; Li, Ming-chuan ; Lin, Yun-hua ; Hou, Zhu ; Han, Yi-li ; Jiang, Yong-guang</creator><creatorcontrib>Luo, Yong ; Wei, Neng-bao ; Zhao, Jia-hui ; Cui, Xin-hao ; Li, Ming-chuan ; Lin, Yun-hua ; Hou, Zhu ; Han, Yi-li ; Jiang, Yong-guang</creatorcontrib><description>To explore the prognostic factors of prostate cancer (PCa) patients and evaluate the effect of brachytherapy on survival time.
A total of 289 PCa were recruited to collect their clinical and survival data. And their possible prognostic factors were analyzed. A further comparison of 5-year cumulative survival rate was made between the patients treated by maximal androgen blockade (MAB) and those on MAB plus brachytherapy.
Their median survival time was 73 (7-144) months. And the 1, 3 and 5-year survival rates were 93.1%, 81.0% and 60.2% respectively. Univariate analysis indicated that prostate volume, basal level of prostate-specific antigen (PSA), Gleason score, tumor stage, PSA nadir, time PSA decreasing to nadir and brachytherapy were all predictive factors for survival time. And multivariate analysis further demonstrated that Gleason score, tumor stage and PSA nadir were independent prognostic indicators. And the combination therapy based on brachytherapy could significantly increase the 5-year cumulative</description><identifier>ISSN: 0376-2491</identifier><identifier>DOI: 10.3760/cma.j.issn.0376-2491.2013.42.007</identifier><identifier>PMID: 24418030</identifier><language>chi</language><publisher>China</publisher><subject>Aged ; Aged, 80 and over ; Androgen Antagonists - therapeutic use ; Brachytherapy ; Combined Modality Therapy ; Humans ; Male ; Middle Aged ; Prognosis ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - therapy ; Retrospective Studies ; Survival Rate ; Treatment Outcome</subject><ispartof>Zhong hua yi xue za zhi, 2013-11, Vol.93 (42), p.3351-3354</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24418030$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Luo, Yong</creatorcontrib><creatorcontrib>Wei, Neng-bao</creatorcontrib><creatorcontrib>Zhao, Jia-hui</creatorcontrib><creatorcontrib>Cui, Xin-hao</creatorcontrib><creatorcontrib>Li, Ming-chuan</creatorcontrib><creatorcontrib>Lin, Yun-hua</creatorcontrib><creatorcontrib>Hou, Zhu</creatorcontrib><creatorcontrib>Han, Yi-li</creatorcontrib><creatorcontrib>Jiang, Yong-guang</creatorcontrib><title>Long-term outcomes of prostate cancer patients treated with combined brachytherapy and maximal androgen blockade</title><title>Zhong hua yi xue za zhi</title><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><description>To explore the prognostic factors of prostate cancer (PCa) patients and evaluate the effect of brachytherapy on survival time.
A total of 289 PCa were recruited to collect their clinical and survival data. And their possible prognostic factors were analyzed. A further comparison of 5-year cumulative survival rate was made between the patients treated by maximal androgen blockade (MAB) and those on MAB plus brachytherapy.
Their median survival time was 73 (7-144) months. And the 1, 3 and 5-year survival rates were 93.1%, 81.0% and 60.2% respectively. Univariate analysis indicated that prostate volume, basal level of prostate-specific antigen (PSA), Gleason score, tumor stage, PSA nadir, time PSA decreasing to nadir and brachytherapy were all predictive factors for survival time. And multivariate analysis further demonstrated that Gleason score, tumor stage and PSA nadir were independent prognostic indicators. And the combination therapy based on brachytherapy could significantly increase the 5-year cumulative</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Brachytherapy</subject><subject>Combined Modality Therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0376-2491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1PwzAMhnMAsQn2F1COu7Q4SdukRzTxJU3iAucqTbyt0KYlSQX79wQxONl-9MiyX0LWDHIhK7gxg87f8i4El0MCGS9qlnNgIi94DiDPyPKfL8gqhK6FQoqaA2cXZMGLgikQsCTTdnT7LKIf6DhHMw4Y6Lijkx9D1BGp0c6gp5OOHboYaPSYsKWfXTzQpLedS1PrtTkc4wG9no5UO0sH_dUNuv_p_bhHR9t-NO_a4hU53-k-4OpUL8nr_d3L5jHbPj88bW632cR4FTPLSkCrrGCVUVzZqrKV2kksFJetFNLUSnBVcigtiFJUpa00r2sGgFIrAeKSrH_3plc-ZgyxGbpgsO-1w3EODStqkDIlxpJ6fVLndkDbTD6d7o_NX0riG_DEbaA</recordid><startdate>20131112</startdate><enddate>20131112</enddate><creator>Luo, Yong</creator><creator>Wei, Neng-bao</creator><creator>Zhao, Jia-hui</creator><creator>Cui, Xin-hao</creator><creator>Li, Ming-chuan</creator><creator>Lin, Yun-hua</creator><creator>Hou, Zhu</creator><creator>Han, Yi-li</creator><creator>Jiang, Yong-guang</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20131112</creationdate><title>Long-term outcomes of prostate cancer patients treated with combined brachytherapy and maximal androgen blockade</title><author>Luo, Yong ; Wei, Neng-bao ; Zhao, Jia-hui ; Cui, Xin-hao ; Li, Ming-chuan ; Lin, Yun-hua ; Hou, Zhu ; Han, Yi-li ; Jiang, Yong-guang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-d150ed8d316c828d66d68f7e4827b737c983285205d035365d6a299100e7a8303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Brachytherapy</topic><topic>Combined Modality Therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Luo, Yong</creatorcontrib><creatorcontrib>Wei, Neng-bao</creatorcontrib><creatorcontrib>Zhao, Jia-hui</creatorcontrib><creatorcontrib>Cui, Xin-hao</creatorcontrib><creatorcontrib>Li, Ming-chuan</creatorcontrib><creatorcontrib>Lin, Yun-hua</creatorcontrib><creatorcontrib>Hou, Zhu</creatorcontrib><creatorcontrib>Han, Yi-li</creatorcontrib><creatorcontrib>Jiang, Yong-guang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhong hua yi xue za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luo, Yong</au><au>Wei, Neng-bao</au><au>Zhao, Jia-hui</au><au>Cui, Xin-hao</au><au>Li, Ming-chuan</au><au>Lin, Yun-hua</au><au>Hou, Zhu</au><au>Han, Yi-li</au><au>Jiang, Yong-guang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term outcomes of prostate cancer patients treated with combined brachytherapy and maximal androgen blockade</atitle><jtitle>Zhong hua yi xue za zhi</jtitle><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><date>2013-11-12</date><risdate>2013</risdate><volume>93</volume><issue>42</issue><spage>3351</spage><epage>3354</epage><pages>3351-3354</pages><issn>0376-2491</issn><abstract>To explore the prognostic factors of prostate cancer (PCa) patients and evaluate the effect of brachytherapy on survival time.
A total of 289 PCa were recruited to collect their clinical and survival data. And their possible prognostic factors were analyzed. A further comparison of 5-year cumulative survival rate was made between the patients treated by maximal androgen blockade (MAB) and those on MAB plus brachytherapy.
Their median survival time was 73 (7-144) months. And the 1, 3 and 5-year survival rates were 93.1%, 81.0% and 60.2% respectively. Univariate analysis indicated that prostate volume, basal level of prostate-specific antigen (PSA), Gleason score, tumor stage, PSA nadir, time PSA decreasing to nadir and brachytherapy were all predictive factors for survival time. And multivariate analysis further demonstrated that Gleason score, tumor stage and PSA nadir were independent prognostic indicators. And the combination therapy based on brachytherapy could significantly increase the 5-year cumulative</abstract><cop>China</cop><pmid>24418030</pmid><doi>10.3760/cma.j.issn.0376-2491.2013.42.007</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-2491 |
| ispartof | Zhong hua yi xue za zhi, 2013-11, Vol.93 (42), p.3351-3354 |
| issn | 0376-2491 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_1490770131 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Aged Aged, 80 and over Androgen Antagonists - therapeutic use Brachytherapy Combined Modality Therapy Humans Male Middle Aged Prognosis Prostatic Neoplasms - diagnosis Prostatic Neoplasms - mortality Prostatic Neoplasms - therapy Retrospective Studies Survival Rate Treatment Outcome |
| title | Long-term outcomes of prostate cancer patients treated with combined brachytherapy and maximal androgen blockade |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T17%3A19%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20outcomes%20of%20prostate%20cancer%20patients%20treated%20with%20combined%20brachytherapy%20and%20maximal%20androgen%20blockade&rft.jtitle=Zhong%20hua%20yi%20xue%20za%20zhi&rft.au=Luo,%20Yong&rft.date=2013-11-12&rft.volume=93&rft.issue=42&rft.spage=3351&rft.epage=3354&rft.pages=3351-3354&rft.issn=0376-2491&rft_id=info:doi/10.3760/cma.j.issn.0376-2491.2013.42.007&rft_dat=%3Cproquest_pubme%3E1490770131%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490770131&rft_id=info:pmid/24418030&rfr_iscdi=true |